What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “HRS-5635 Injection (high dose) and Peg-IFN-α, administered by subcutaneous injection”In the company’s words, NCT06425341 on ClinicalTrials.gov
- Tested for
- Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B, Chronic Hepatitis B
- Main trialPhase 3
- “This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and immunogenicity of HRS-5635 injection as compared to the placebo arm in nucleos(t)ide analogue-suppressed HBeAg-negative patients with chronic hepatitis B. The total duration of the study, including screening (up to 4 weeks), the double-blind treatment stage (60 weeks),NAs-only treatment stage(12 weeks) and the off-treatment follow-up (24 weeks), is up to approximately 100 weeks at maximum for each participant.”In the company’s words, NCT07606950 on ClinicalTrials.gov
Other drugs for Chronic Hepatitis B
- GST-HG141Fujian Akeylink Biotechnology Co., Ltd. · Phase 3
- AHB-137Ausper Biopharma Co., Ltd. · Phase 3
- ZM-H1505RShanghai Zhimeng Biopharma, Inc. · Phase 3
- TQA3605Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Tenofovir DFGilead (Kite) · Phase 3
- HT-101Suzhou HepaThera Biotech Co., Ltd. · Phase 2
Coming up1
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2028 | Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B | |
| Phase 2Recruiting | 30 Aug 2026 | A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B | |
| Phase 1Unknown | 31 May 2024 | Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026